Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer

被引：0
|
作者：
Pauline Corbaux
Audrey Lardy-Cleaud
Marie Alexandre
Maxime Fontanilles
Christelle Lévy
Alessandro Adriano Viansone
Audrey Mailliez
Marc Debled
Anthony Goncalves
Fanny Le Du
Florence Lerebours
Jean-Marc Ferrero
Jean-Christophe Eymard
Marie-Ange Mouret-Reynier
Thierry Petit
Jean-Sébastien Frenel
Florence Dalenc
Coralie Courtinard
Marie Chaix
Thomas Bachelot
机构：
[1] Centre Léon Bérard,Department of Medical Oncology
[2] Centre Léon Bérard,Biostatistics Unit, DRCI
[3] Institut Régional du Cancer de Montpellier,Department of Medical Oncology
[4] Centre Henri Becquerel,Department of Medical Oncology
[5] Centre François Baclesse,Department of Medical Oncology
[6] Institut Gustave Roussy,Department of Cancer Medicine
[7] Centre Oscar Lambret,Department of Medical Oncology
[8] Institut Bergonié,Department of Medical Oncology
[9] Institut Paoli-Calmettes,Department of Medical Oncology
[10] Centre Eugène Marquis,Department of Medical Oncology
[11] Institut Curie,Department of Medical Oncology
[12] Centre Antoine Lacassagne,Department of Medical Oncology
[13] Institut Jean Godinot,Department of Medical Oncology
[14] Centre Jean Perrin,Department of Medical Oncology
[15] Centre Paul Strauss,Department of Medical Oncology
[16] Institut de Cancérologie de l’Ouest René Gauducheau,Department of Medical Oncology
[17] Institut Claudius Regaud—IUCT Oncopole,Department of Medical Oncology
[18] Unicancer,Data Office
[19] Université de Bordeaux,Inserm, Bordeaux Population Health Research Center, Epicene Team, UMR 1219
[20] Centre Hospitalier Universitaire Dijon Bourgogne,Department of Medical Oncology
来源：
Breast Cancer Research and Treatment | 2022年 / 191卷
关键词：
Advanced breast cancer; HR+/HER2−; Endocrine therapy; Chemotherapy; Progression-free survival; Real-word data;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：191 / 207
页数：16
相关论文
共 50 条
  • [41] A Representative Clinical Course of Progression, with Molecular Insights, of Hormone Receptor-Positive, HER2-Negative Bone Metastatic Breast Cancer
    Magno, Elizabeth
    Bussard, Karen M.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (06)
  • [42] Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy
    Pernas, Sonia
    Sanfeliu, Esther
    Villacampa, Guillermo
    Salvador, Javier
    Perello, Antonia
    Gonzalez, Xavier
    Jimenez, Begona
    Merino, Maria
    Palacios, Patricia
    Pascual, Tomas
    Alba, Emilio
    Villanueva, Lorea
    Chillara, Samyukta
    Ferrero-Cafiero, Juan Manuel
    Galvan, Patricia
    Prat, Aleix
    Ciruelos, Eva
    NPJ BREAST CANCER, 2024, 10 (01)
  • [43] Patterns of chemotherapy receipt among patients with hormone receptor-positive, HER2-negative breast cancer
    Olsson, Linnea T.
    Hamilton, Alina M.
    Van Alsten, Sarah C.
    Lund, Jennifer L.
    Sturmer, Til
    Nichols, Hazel B.
    Reeder-Hayes, Katherine E.
    Troester, Melissa A.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 204 (01) : 107 - 116
  • [44] HER2 up-regulation with neoadjuvant endocrine therapy in patients with hormone receptor-positive, HER2-negative breast cancer
    Chaudhary, Lubna N.
    Jorns, Julie
    Gonyo, MaryBeth
    Kong, Amanda
    Peck, Amy R.
    Sun, Yunguang
    Bergom, Carmen
    Banarjee, Anjishnu
    Chitambar, Christopher
    Rui, Hallgeir
    CANCER RESEARCH, 2020, 80 (04)
  • [45] Ribociclib plus endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled safety analysis
    Burris, H. A.
    Chan, A.
    Im, S-A
    Chia, S.
    Tripathy, D.
    Esteva, F. J.
    Campone, M.
    Bardia, A.
    Kong, O.
    Bao, W.
    Diaz-Padilla, I.
    Lorenc, K. Rodriguez
    Yardley, D. A.
    CANCER RESEARCH, 2019, 79 (04)
  • [46] Effectiveness and Safety of Palbociclib plus Endocrine Therapy in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Real-World Results
    Fernandez-Cuerva, C.
    Del Rio, Valencia J. C.
    Bermejo, R. T.
    CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2022, 75 (02): : 128 - 128
  • [47] Effectiveness and Safety of Palbociclib plus Endocrine Therapy in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Real-World Results
    Fernandez-Cuerva, Cristina
    Valencia, Juan Carlos del Rio
    Tamayo Bermejo, Rocio
    CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2022, 75 (01): : 26 - 33
  • [48] Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study
    Tolaney, Sara M.
    Beeram, Muralidhar
    Beck, J. Thaddeus
    Conlin, Alison
    Dees, E. Claire
    Puhalla, Shannon L.
    Rexer, Brent N.
    Burris, Howard A., III
    Jhaveri, Komal
    Helsten, Teresa
    Becerra, Carlos
    Kalinsky, Kevin
    Moore, Kathleen N.
    Manuel, Allison M.
    Lithio, Andrew
    Price, Gregory L.
    Chapman, Sonya C.
    Litchfield, Lacey M.
    Goetz, Matthew P.
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [49] Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    Burstein, Harold J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12): : 1176 - 1177
  • [50] Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    Burstein, Harold J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (26): : 2557 - 2570
12345